Nordic Issuing

Ongoing case

DanCann Pharma A/S

Back to all cases

DanCann Pharma A/S

7 Oct - 23 Oct 2020IPO

DanCann Pharma A/S was founden in 2018 and is a Danish pharmaceutical and biotech company with their business within cannabionoids. Their foucs is to discover, develop, manufacture and commercialize new cannabionoid pharmaceuticals within a broad spectra of hostpial areas.

The company was founded due to a lack of availability of cannabinoid based pharmaceuticals shortly after the new pilot programme for medical cannabis in Denmark was launched.

DanCann Pharma is licensed to handle euphorical substances, and during the summer of 2018 they received a license as one of the first companies to handle and farm cannabis for medical use.

The company produces and distributes prescripted pharmaceuticals (Rx pharmaceuticals) and prescription free pharmaceuticals (OTC), mainly focused on pain patients and alternative treatment to handle their diseases, covered by the Danish pilot programme for medical cannabis, aiming at new groups of patiemts and additional segments.

Read more on the company's website

The offer in summary

Subscription period: 7 oktober - 23 oktober

Price per unit: 22.50 DKK

Minimum subscription : 200 units

Marketplace: Spotlight Stock Market

First day of trading: Planned to 12 november 2020

Share ISIN: DK0061410487

Warrant ISIN: DK0061410560

Financial advisor: Corpura Fondkommission AB


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.